RxDoctor Payments Data

Carrissa Butts, APRN

Nurse Practitioner · Huntley, ILNPI 1972048528

Payments from drug & device makers

$827in general payments, 2019–2025

Across 27 payments — averaging $30.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lantheus Medical Imaging, Inc.$207
  • Boston Scientific$128
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$127
  • Actelion Pharmaceuticals US, Inc.$88
  • Edwards Lifesciences$82
  • Boehringer Ingelheim$67
  • plus $128 from 5 others

What the payments were for

  • Food & beverage$827100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$827 in reported general payments places this provider in the 75th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$60,453
Medicare patients
469
Services billed
708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban114$147,256
XareltoRivaroxaban27$34,306
JardianceEmpagliflozin16$21,628
BrilintaTicagrelor23$20,499
Repatha SureclickEvolocumab12$14,768
EntrestoSacubitril/Valsartan15$12,599
Atorvastatin Calcium268$2,661
Metoprolol Succinate181$2,077
ClopidogrelClopidogrel Bisulfate99$1,834
Carvedilol151$1,328
Rosuvastatin Calcium101$1,148
Amlodipine Besylate117$1,137
Ezetimibe43$1,069
Losartan Potassium92$1,008
Diltiazem 24hr Er (Cd)Diltiazem Hcl29$924

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$67$21,62816 claims
AstraZenecaBrilinta$23$20,49923 claims
NovartisEntresto$35$12,59915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Huntley

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →